Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients ; day:28 ; month:8 ; year:2023 ; pages:1-4
Magazine of European Medical Oncology ; (28.8.2023), 1-4
- Urheber
-
Heregger, Ronald
Greil, Richard
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12254-023-00902-4
- URN
-
urn:nbn:de:101:1-2023110711152621413218
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Heregger, Ronald
- Greil, Richard
- SpringerLink (Online service)
Ähnliche Objekte (12)
Tips for erythropoiesis-stimulating agent treatment of renal anemia
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis
Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy
Role of circulating endothelial progenitors in responsiveness to erythropoiesis-stimulating agents in hemodialysis patients
Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
Tips for erythropoiesis-stimulating agent treatment of renal anemia
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis
Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy
Role of circulating endothelial progenitors in responsiveness to erythropoiesis-stimulating agents in hemodialysis patients
Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
Tips for erythropoiesis-stimulating agent treatment of renal anemia
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis
Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy
Role of circulating endothelial progenitors in responsiveness to erythropoiesis-stimulating agents in hemodialysis patients
Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial